

NX Uranium, Inc and Predecessor Company
(a Development Stage Company)

Consolidated Balance Sheets
(unaudited)

	September 30, 2014	December 31, 2013
Assets		
Current assets:		
Cash and cash equivalents	\$ 1,970	—
Total current assets	1,970	—
Investment in mineral property	50,090	32,770
Total assets	<u>\$ 52,060</u>	<u>32,770</u>
Liabilities and Stockholders' Deficit		
Current liabilities:		
Accounts payable and accrued expenses	\$ 38,750	86,250
Accounts payable and accrued expenses - related party	5,683	—
Advance payable - related party	7,500	—
Total current liabilities	<u>51,933</u>	<u>86,250</u>
Contingency (Note 9)		
Stockholders' deficit:		
Preferred Series A stock, \$0.0001 par value, 25,000,000 shares authorized, 283,333 shares issued and outstanding	28	28
Common stock, \$0.0001 par value, 250,000,000 shares authorized, 10,720,616 and 8,794,433 issued and outstanding, respectively	1,072	879
Additional paid-in-capital	7,764,879	7,562,001
Accumulated deficit from prior operations	(7,439,633)	(7,439,633)
Accumulated deficit during the development stage	<u>(326,219)</u>	<u>(176,755)</u>
Total stockholders' deficit	<u>127</u>	<u>(53,480)</u>
Total liabilities and stockholders' deficit	<u>\$ 52,060</u>	<u>32,770</u>

See accompanying notes to unaudited consolidated financial statements.

NX Uranium, Inc and Predecessor Company
(a Development Stage Company)

Consolidated Statements of Operations
(unaudited)

	For the three months ended September 30,		For the nine months ended September 30,		Period from inception of Development Stage (October 10, 2013) through September 30, 2014
	2014	2013	2014	2013	
Revenue	\$ —	—	—	—	—
Operating expenses:					
Professional fees	53,787	33,703	56,144	79,703	117,394
General and administrative	27,921	7,076	83,319	16,312	83,319
Settlement expenses	—	—	—	—	115,505
Total operating expenses	81,708	40,779	139,463	96,015	316,218
Gross profit	(81,708)	(40,779)	(139,463)	(96,015)	(316,218)
Other expenses:					
Loss on forfeiture of deposit	—	—	(10,000)	—	(10,000)
Interest expense	—	(10,393)	—	(48,713)	—
	—	(10,393)	(10,000)	(48,713)	(10,000)
Net loss before extraordinary items	(81,708)	(51,172)	(149,463)	(144,728)	(326,218)
Extraordinary item - gain on sale of subsidiary	—	2,938,557	—	2,938,557	—
Net income (loss)	\$ (81,708)	2,887,385	(149,463)	2,793,829	(326,218)
Net income (loss) per common share:					
Basic	\$ (0.008)	0.399	(0.016)	0.452	
Diluted	\$ (0.008)	0.276	(0.016)	0.311	
Weighted average common shares outstanding					
Basic	10,145,205	7,233,538	9,578,637	6,176,350	
Diluted	10,145,205	7,779,193	9,578,637	6,710,457	

See accompanying notes to unaudited consolidated financial statements.

NX Uranium, Inc and Predecessor Company
(a Development Stage Company)

Consolidated Statements of Cash Flows
(unaudited)

	For the nine months ended September 30,		Period from inception of Development Stage (October 10, 2013) through September 30, 2014
	2014	2013	
Cash flows from operating activities:			
Net income (loss)	\$ (149,463)	2,793,829	(326,218)
Adjustments to reconcile net income (loss) to net cash used in operating activities:			
Stock-based compensation	127,750	—	127,750
Non-cash settlement expenses	—	—	115,505
Gain on sale of subsidiary	—	(2,938,557)	—
Change in operational assets and liabilities:			
Increase in related party receivable	—	(7,703)	—
Increase in accounts payable and accrued expenses	8,183	103,718	69,433
Increase in accrued interest payable	—	48,713	—
Net cash used in operating activities	<u>(13,530)</u>	<u>—</u>	<u>(13,530)</u>
Cash flows from financing activities:			
Proceeds from sales of common stock	8,000	—	8,000
Advance from related party	<u>7,500</u>	<u>—</u>	<u>7,500</u>
	<u>15,500</u>	<u>—</u>	<u>15,500</u>
Net change in cash and cash equivalents	1,970	—	1,970
Cash and cash equivalents, beginning of period	<u>—</u>	<u>—</u>	<u>—</u>
Cash and cash equivalents, end of period	<u>\$ 1,970</u>	<u>—</u>	<u>1,970</u>
Supplemental schedule of non-cash operating and investing activities:			
Accounts payable settled through issuance of common stock	\$ <u>50,000</u>	<u>—</u>	<u>50,000</u>
Common stock issued for compensation to directors and officers	\$ <u>127,750</u>	<u>—</u>	<u>127,750</u>
Common stock issued for settlement with prior director and officer	\$ <u>—</u>	<u>—</u>	<u>90,505</u>
Settlement expenses included in accounts payable	\$ <u>—</u>	<u>—</u>	<u>25,000</u>

See accompanying notes to unaudited consolidated financial statements.